MaxCyte Inc
NASDAQ:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
G1 Secure Solutions Ltd
TASE:GOSS
|
IL |
|
N
|
Novo Nordisk A/S
XBER:NOV
|
DK |
|
A
|
Aurrigo International PLC
LSE:AURR
|
UK |
|
P
|
POET Technologies Inc
XBER:RI4
|
CA |
|
O
|
OY Nofar Energy Ltd
TASE:NOFR
|
IL |
|
Medion AG
XETRA:MDN
|
DE |
|
B
|
Beijing Infosec Technologies Co Ltd
SSE:688201
|
CN |
|
C
|
CSMall Group Ltd
HKEX:1815
|
CN |
|
Clevo Co
TWSE:2362
|
TW |
|
Actia Group SA
PAR:ALATI
|
FR |
|
Bank of India Ltd
NSE:BANKINDIA
|
IN |
|
Dont Nod Entertainment SA
PAR:ALDNE
|
FR |
|
Hindustan Petroleum Corp Ltd
NSE:HINDPETRO
|
IN |
|
Magazine Luiza SA
BOVESPA:MGLU3
|
BR |
|
D
|
DCM Financial Services Ltd
NSE:DCMFINSERV
|
IN |
|
HubSpot Inc
NYSE:HUBS
|
US |
|
C
|
Cardinal Health Inc
XBER:CLH
|
US |
MaxCyte Inc
Operating Expenses
MaxCyte Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Operating Expenses
-$71.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-23%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Operating Expenses
-$10.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
|
|
Danaher Corp
NYSE:DHR
|
Operating Expenses
-$9.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Waters Corp
NYSE:WAT
|
Operating Expenses
-$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-6%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Operating Expenses
-$2.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Operating Expenses
-$3.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-13%
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
See Also
What is MaxCyte Inc's Operating Expenses?
Operating Expenses
-71.3m
USD
Based on the financial report for Dec 31, 2025, MaxCyte Inc's Operating Expenses amounts to -71.3m USD.
What is MaxCyte Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-23%
Over the last year, the Operating Expenses growth was 14%. The average annual Operating Expenses growth rates for MaxCyte Inc have been -2% over the past three years , -16% over the past five years , and -23% over the past ten years .
